Abstract
The market for diagnostic and molecular imaging (MI) products has had a rocky
time in recent years; cost controls and the economic downturn have conspired
to peg back the sector's growth. But since 2010 things have improved; pressure
in the US market has eased and growth has come from increasing demand in
emerging markets such as India and China. The nuclear imaging segment has not
been unaffected. Ongoing supply issues of radiopharmaceuticals and negative
reimbursement development have impacted SPECT to the benefit of PET.
What does the future hold for the companies and organisations that are investing US$ billions in developing molecular imaging products?
Since 2010, the market has seen stronger growth, helped by demand in
under-penetrated markets, the adoption of newer-generation hybrid imaging
technologies such as PET/CT and a move towards the use of PET from SPECT,
necessitating the purchase of new PET systems.
The short-lived positron-emitting isotopes used in PET imaging are generally
produced in a cyclotron and then synthesised on-site before patient
administration. Although not requiring the use of a nuclear reactor, this
limits the use of PET imaging to centres with access to a cyclotron and
synthesis equipment. Therefore, a major development is the recent availability
of smaller and cheaper cyclotrons which are designed to produce C-11 and F-18
isotopes economically and on-demand, without the need for radiochemistry or
PET accelerator expertise.
The drive towards PET has been additionally boosted by advancement in the
diagnosis of Alzheimer's disease and the approval of Avid
Radiopharmaceuticals' Amyvid (florbetapir F-18 injection). Avid (owned by Eli
Lilly) is the first company to achieve approval for a diagnostic PET tracer
which estimates beta amyloid neuritic plaque density in adults with cognitive
impairment. This is likely to become a busy marketplace with GE, Piramel and
Navidea developing late-stage products whilst the focus of new research is
targeting the tau proteins.
With this report you will:
- Know the state of the molecular imaging market and recent advances in
Alzheimer's diagnosis
- Establish the future market growth with 5-year value forecasts
- Know the clinical and regulatory challenges facing the sector
- Assess the companies that are developing hybrid technologies
- Review the challenges facing producers of radiopharmaceuticals and the
research which is seeking alternative paths
- Know why PET is outpacing SPECT and the advantages it brings
- Appreciate the regulatory hurdles affecting radiopharmaceutical producers
in the US
- Understand the changing competitive landscape and market positioning of
new entrants
The MI market fundamentals remain solid and there are strong opportunities for
growth within the industry. These are being driven by continued innovation and
new product development, beneficial demographics, an ageing installed base of
imaging equipment in the developed markets of the US and Europe, and the
increasing adoption of MI technologies in emerging markets.
In particular, the increasing incidence of cancer, cardiovascular and
neurological diseases means that demand for faster and more accurate
diagnosis, as well as drug development and pre-clinical study efforts, will
continue to accelerate in coming years. In addition, MI technologies will
become more widely adopted as clinical evidence is established as to their
benefits, and new technological innovations continue to be brought to market,
particularly related to the MI of cancer and neurological diseases such as
Alzheimer's and Parkinson's.
In addition, the current lack of penetration for nuclear and molecular imaging
in emerging economies is driving demand, where new facilities are being set up
and lower-cost systems are in demand.
Challenges to overcome
The short and mid-term prospects for MI are to a large extent dependant on the
pace of economic recovery, which will affect the ability of smaller companies
to obtain financing and future healthcare budgets, particularly in Europe. In
addition, uncertainties currently exist surrounding Mo-99 supply, the impact
of the US medical device excise tax, new regulatory hurdles for
radiopharmaceuticals in the US and whether beta amyloid PET imaging (and
related technologies) will be sufficiently reimbursed to facilitate their
widespread use.
A changing competitive landscape
Currently, the key players in the MI market include medical diagnostic imaging
equipment manufacturers such as Philips, Siemens and GE; radiopharmaceutical
and imaging agent companies such as GE, Bracco, Covidien, IBA Molecular and
Lantheus Medical Imaging; and companies that operate radiopharmacies such as
Cardinal Health, Triad Isotopes and Siemens. The landscape is shifting and,
despite pharmaceutical companies such as BMS and Bayer leaving the MI market,
others have been keen to enter.
- Piramal Group has gained a strong position in MI. The company now owns the
intellectual property and development, marketing and distribution rights for
Bayer's lead compound, florbetaben, which is seen as a promised imaging agent
for AD. Through the Bayer transaction, Piramal now also owns other clinical
and pre-clinical agents that are in development for cardiology and oncology
imaging.
- Progenics Pharmaceuticals is focusing on developing therapeutic
radiopharmaceuticals and targeted MI agents for oncology, through its
acquisition of Molecular Insight Pharmaceuticals.
And it is not just Pharma companies:
- PerkinElmer has acquired VisEn Medical and Caliper Lifesciences, who's in
vivo and in vitro diagnostics are used in pre-clinical drug development work.
- Samsung has strengthened its medical imaging business with the
acquisition, in January 2013, of NeuroLogica. Although mainly focused on
portable CT scanners, NeuroLogica also offers the inSPira HD portable SPECT
system.
The report covers companies active in the major MI sectors
- Nuclear Imaging
- Near infrared or optical imaging
- Ultrasound
- MRI
- MRI/PET
- MRI/SPECT
- Tracers and Radiopharmaceuticals
This report answers key business questions...
- What alternatives are being considered to mitigate the ongoing supply
issues with the Molybdenum-99 isotope?
- In which therapy sectors are MI technologies playing a key diagnostic role
and with what success?
- What collaborative role are academic institutions playing in MI
development?
- Which companies are most advanced in introducing hybrid imaging systems?
- For which tracing agent did Navidea receive FDA approval in March 2013?
- Which 2 Spanish companies did Advanced Accelerator Applications acquire in
January 2013?
- What development in 2012 strengthened Bruker's position in the
pre-clinical imaging sector?
- What developments are helping GE maintain its leading position in the
molecular imaging sector?
About the Author
This report has been researched and written by experienced and independent
medical market analyst Joanne Maddox. For over 13 years she has played a
pivotal role in tracking trends in medical device and equipment markets and
companies. A former editor of Medical Device Companies Analysis she has also
written Medical IT: Understanding the major players and products; All Change
in the Advanced Wound Care Market and Point of Care Diagnostics: Players,
Products and Prospects.
About the Publisher
Espicom Business Intelligence is a leading provider of specialist health
industry market information. Based in the UK and with over 30 years of
experience, the company produces a broad range of business and therapy titles
and is uniquely placed to publish this report. Espicom is part of Business
Monitor International.
Table of Contents
EXECUTIVE SUMMARY
INTRODUCTION
- Applications of MI
- Neurological Disease
- Oncology
- Cardiovascular Disease
- MI for use in LifeSciences and the Phmaceutical Industry
- MI Modalities
- Hybrid MRI/PET Imaging
- Hybrid MRI/SPECT Imaging
- Tracers and Radiopharmaceuticals
COMPETITIVE LANDSCAPE
- New Market Entrants
- Market Consolidation
- Collaborative Development Efforts
- Barriers to Market Entry and Challenges for Smaller Companies
CURRENT MARKET DYNAMICS
- Nuclear Imaging Adoption
- Market Insight
- Fig.1: Diagnostic Imaging Systems Market by Modality, 2012
- Fig.2: Medical Imaging Market, 2005-2012 (US$ billion)*
- Fig.3: Nuclear Imaging Equipment Market, 2007-2012 (US$ billion)*
- Fig.4: Molecular Imaging Market by End-Use Product Type, 2010
- Molybdenum-99 Isotope Supply Issues
- Recent Developments in the PET Market
- Alzheimer's Disease PET Imaging
- Lymphoseek Lymph Node Imaging
- PET Regulatory Approval Issues
- Improved Optical Imaging Techniques
MARKET OUTLOOK
- Molecular Imaging: Market Drivers, Restraints & Future Opportunities
- Fig.5: Nuclear Imaging Equipment Market, 2012-2017E (US$ million)*
- Fig.6: Pre-Clinical Imaging Systems Market, 2012-2017E (US$ million)
- Fig.7: Radiopharmaceuticals Market, 2012-2017E (US$ million)
- Fig.8: Molecular Imaging End-Use Products Market, 2012-2017E (US$ million)*
MOLECULAR IMAGING COMPANIES
ABT MOLECULAR IMAGING
- "Dose on Demand" Biomarker Generator
ABX
ADVANCED ACCELERATOR APPLICATIONS
- Recent Events
- Mergers and Acquisitions
- Products
- Research & Development: Annexin V-128
- Current Alliances
- UWRC SPÓ£KA Z OGRANICZONA ODPOWIEDZIALNOŚCIA,
University of Warsaw
- GE Healthcare
- Institut Curie
- IASON GmbH
- European Molecular Imaging Manufacturers Association
- Bracco
- Financial Performance
ADVANCED CYCLOTRON SYSTEMS
- Recent Events
- Products
- TR 24 Cyclotrons
- TR 30 Cyclotrons
- TR PET Cyclotrons
- CycloTec R&D Programme
- Current Alliances
ADVANCED MEDICAL ISOTOPE
- Products in Development
- US Production of Molybdenum-99
- Alliance with GSG International
- Financial Performance
- AMIC - Operating Results, 2007-2011 (US$ thousand)
- Fig.9: AMIC - Revenue by Type, 2011
- Latest Results
AFFIBODY
- ABY-025 HER2-Binding Affibody Imaging Agent
- Alliance with GE Healthcare
AGENIX
- ThromboView
- Pulmonary Embolism Application
- Deep Vein Thrombosis
ALSERES PHARMACEUTICALS
- Altropane
- Navidea Biopharmaceuticals Licence Agreement
ANTICANCER
- Current Alliances
- UVP
- Caliper Life Sciences (PerkinElmer)
- INDEC Systems
- Olympus
APOSENSE
- [18F]-ML-10 and EarliTest
- Current Agreements
ART ADVANCED RESEARCH TECHNOLOGIES
- ART: Recent Events
- Products
- Optix MX3
- SoftScan Optical Breast Imaging System
- Fenestra Contrast Agents
ASTELLAS PHARMA
- Lexiscan (regadenoson)
- Adenoscan (adenosine injection)
- Cardiac Imaging Revenue
- Fig.10: Astellas Pharma's Cardiac Imaging Sales, Fiscal 2008-2011 (US$
million)
AVID RADIOPHARMACEUTICALS (ELI LILLY)
- Amyvid (florbetapir F 18 injection)
- Products in Development
- Current Alliances
- Cardinal Health
- PETNET Solutions (Siemens)
- Piramal Imaging
BIOSCAN
- Pre-Clinical Imaging Products
- BioFLECT
- NanoSPECT/CT and NanoPET/CT
- HiSPECT
- IMAPPI Consortium
BIOSPACE LAB
- Recent Key Events
- Products
- Photon Imager Systems
- Beta Imager.
- Current Alliances
- Centre for Advanced Biomedical Imaging at University College London
- ImaBio Group
BRACCO
- Products
- Research and Development
- Ultrasound MI Contrast Agents
- Current Alliances
- Rete Ventures
- Nordion
- Advanced Accelerator Applications (AAA)
- ImaRx Therapeutics
- VisualSonics
BRUKER
- Recent Key Events
- Products
- Pre-Clinical MRI
- Albira PET/SPECT/CT System
- In Vivo Optical Imaging Solutions
- Current Alliances
- Philips
- Aspect Imaging
- University of York, UK
- Iseult Programme
- Siemens
BV CYCLOTRON VU
- Products
- Current Alliances
- IBA Group
- Alliance with VU University Medical Centre
CARDINAL HEALTH
- Recent Key Events
- Imaging Facilities
- Products
- Current Alliances and Collaborations
- Lantheus Medical Imaging
- Eli Lilly
- ProVision Healthcare
- University of Washington
- American College of Radiology Imaging Network
- Ohio Third Frontier and Ohio State University
- Eckert & Ziegler
- GE Healthcare
- Navidea Biopharmaceuticals
CELLPOINT
- Recent Key Events
- EC Technology
- 99mTc-EC-G for Oncology
- 99mTc-EC-G for Cardiology
- 99mTc-EC-Metronidazole for Stroke and Tumour Hypoxia
- N4 Technology
- Dual Agent Technology
- Beta Cell Technology
- Current Alliances
- Hanmi Pharmaceutical and HYUN IMC
- MJM Productos Farmaceuticos e de Radioprotecao
- Philips Healthcare
- M D Anderson Cancer Center
COVIDIEN (MALLINCKRODT)
- Recent Key Events
- Mallinckrodt PLC
- Products
- Current Alliances
- Rapidscan Pharma Solutions
- Positron
- Institute of Atomic Energy, Poland
- Financial Performance
- Fig.11: Covidien's Imaging Sales, 2006-2012 (US$ million)
- Mallinckrodt in Fiscal 2012
- Mallinckrodt plc - Revenue by Division, 2010-2012 (US$ million)
- Fig.12: Mallinckrodt plc - Revenue by Division, 2012
- Mallinckrodt Global Medical Imaging - Revenue by Geographic Region,
2010-2012 (US$ million)
- Fig.13: Mallinckrodt Global Medical Imaging - Revenue by Geographic
Region, 2012
- Mallinckrodt Global Medical Imaging - Revenue by Key Product, 2010-2012
(US$ million)
- Fig.14: Mallinckrodt Global Medical Imaging - Revenue by Key Product,
2012
- Latest Results
CYCLOPHARMA
DIGIRAD
- Recent Key Events
- Products
- Alliance with Dilon Diagnostics
- Financial Performance
- Digirad - Operating Results, 2008-2012 (US$ million)
- Fig.15: Digirad - Revenue by Division, 2012
DILON DIAGNOSTICS
- Recent Key Events
- Dilon 6800 Gamma Camera
- Dilon 6800 Acella
- GammaLõc
- declipseSPECT
- Recent BSGI Clinical Trial Results
- Current Alliances and Contracts
- SurgicEye
- PenRad
- Digirad
- Terason Ultrasound
ECKERT & ZIEGLER
- Recent Key Events
- Products and Services
- Isotope Products
- Radiopharma Products
- Contracts and Alliances
- Euromedic International
- ZAG Zyklotron
- Polish Medical University of Gdansk
- Cardinal Health
- Financial Performance
ECZACIBAŞI-MONROL NUCLEAR PRODUCTS
ERIGAL
FLUOROPHARMA MEDICAL
- Product Pipeline
- CardioPET
- BFPET
- VasoPET
- AZPET
GAMMA MEDICA-IDEAS
- LumaGEM Molecular Breast Imaging System
- Pre-Clinical Imaging
GE HEALTHCARE
- Recent Key Events
- Products
- PET/CT +MR Imaging Platform
- SPECT Systems
- SPECT/CT Systems
- Alcyone Technology Nuclear Imaging Products
- Ventri Nuclear Cardiology System
- PET/CT
- PET Radiopharmacy Products
- Nuclear and Molecular Imaging Agents
- Research and Development
- Research Projects
- Research Collaborations
- Distribution and Other Agreements
- Advanced Accelerator Applications (AAA)
- Rapidscan Pharma Solutions
- Nihon Medi-Physics Joint Venture with Sumitomo Chemical
- Lantheus Medical Imaging
- Financial Performance
- GE Healthcare Operating Results, 2007-2012 (US$ million)
- Fig.16: GE Healthcare - Revenue by Product Area, 2011*
GUERBET
- Research and Development
- Current Alliances and Collaborations
- Gallimed Project - Nordion and Cyceron
- IMAkinib
- Iseult Programme
- Other Projects
HAMAMATSU PHOTONICS
- Products
- Animal PET Scanner SHR-7700
- Research and Development
- Reflectance Diffuse Optical Tomography
IBA GROUP
- Recent Key Events
- MI Products and Services
- IBA Molecular - Radiopharmaceuticals
- IBA RadioPharma Solutions
- Research and Development
- Current Alliances and Contracts
- Piramal Imaging
- Novation
- KeyMarker Consortium
- Servicio Andaluz de Salud, Spain
- Dehnel - Particle Accelerator Components and Engineering
- CEA, France, and IRE, Belgium
- Bio Molecular Industries
- Aposense
- BV Cyclotron VU
- Hae Dong Co Ltd
- Lantheus Medical Imaging
- Wilex
- Financial Performance
IMAGINAB
- Recent Key Events
- Grants and Financing
- Research Projects
- Current Alliances and Contracts
- Oxford Biomedica
- H Lundbeck
- MacroGenics
- Singapore Radiopharmaceuticals
- BZL Biologics
- GE Imanet
- KeyMarker Consortium
- University of California, Los Angeles
- Dainippon Seiki
- Eurogentec
- Singapore's Agency for Science, Technology and Research
- GlaxoSmithKline
IMAGING DIAGNOSTIC SYSTEMS
- CTLM System
- FDA Approval Application
- Fluorescence and Molecular Imaging
- Laser Imager for Lab Animals (LILA)
- Financial Performance
- IDSI - Operating Results, 2008-2012 (US$)
- Latest Results
IMMUNOMEDICS
- LeukoScan
- Research and Development
- TF2 for Colorectal Cancer Imaging and Radioimmunotherapy
- Peptides for Imaging
INDEC SYSTEMS
INTRAMEDICAL IMAGING
JAZZ PHARMACEUTICALS
- ProstaScint
- JUBILANT DRAXIMAGE
- Products
- Ruby-Fill Sr-82/Rb-82 Generator and Rubidium Elution System
- DRAXIMAGE Sestamibi
- Research and Development
- Current Alliances
LANTHEUS MEDICAL IMAGING
- Recent Key Events
- Products
- TechneLite (Technetium Tc99m Generator) and LEU TechneLite
- ABLAVAR (Gadofosveset Trisodium)
- Cardiolite
- Neurolite
- DEFINITY, Neurolite and Cardiolite Supply Issues
- Research and Development
- Flurpiridaz F 18
- LMI 1195 for Cardiac PET Imaging
- BMS 753951
- Current Alliances and Contracts
- Institute for Radioelements, Belgium
- FUJIFILM RI Pharma
- Nordion
- NTP Radioisotopes
- Jubilant HollisterStier
- Ben Venue Laboratories
- Premier Purchasing Partners
- Cardiolite and TechneLite Distribution Agreements
- Australian Nuclear Science and Technology Organisation
- IBA Group
- Financial Performance
- Lantheus Medical Imaging - Operating Results, 2007-2011 (US$ million)
- Lantheus Medical Imaging - Sales by Key Product Line, 2008-2011 (US$
million)
- Fig.17: Lantheus Medical Imaging - Revenue by Product Line, 2011
- Latest Results
LIGHTOOLS RESEARCH
- MI Products
- Pan-A-See-Ya Panorama
- Macro-Illumination Imaging System
- Macro-Imaging System Plus
MEDISO MEDICAL IMAGING SYSTEMS
- Recent Key Events
- nanoScan Pre-Clinical Imaging
- nanoScan SPECT/MRI
- nanoScan PM PET/MRI
- Clinical Imaging
- AnyScan SPECT-CT-PET
- Nucline Gamma Cameras
- Current Alliances and Collaborations
- SPADnet
- INSERT
- Absolute Imaging Solutions
- Aspect Imaging
MILABS
- Products
- Quick-Start SPECT (U-SPECTQS)
- U-SPECT-II/CT
- U-SPECT Scanners
- Current Alliances
- Mid-Atlantic Imaging Services
NAVIDEA BIOPHARMACEUTICALS
- Recent Key Events
- Lymphoseek
- Research and Development
- Expanded Indications for Lymphoseek
- RIGScan
- NAV5001 [123I]-E-IACFT Injection (Altropane)
- NAV4694
- Current Alliances and Licences
- Alseres Pharmaceuticals
- AstraZeneca
- Dow Chemical Company
- Laureate Pharma
- Cardinal Health
- University of California, San Diego
NAVISCAN
- Recent Key Events
- Positron Emission Mammography Scanner
- PEM Clinical Study Results
- Stereo Navigator
- MIMviewer PEM
- Current Alliances
- Ledford Medical Electronics
- Chindex Medical
- Tecnologie Avanzate
- Nuclear Medicine Distributors
- SCETI
- Hae Dong Co Ltd
- MIMVista
NEUROLOGICA (SAMSUNG ELECTRONICS)
NORDION
- Recent Key Events
- Products
- Current Alliances
- The Open Joint Stock Company "Isotope" and Research Institute of Atomic
Reactors, Russia
- Lantheus Medical Imaging
- Gallimed Project - Guerbet and Cyceron
- Bracco
- TRIUMF and the University of British Columbia
- University of Ottawa Heart Institute
- Financial Performance
- Nordion - Results from Continuing Operations, 2010-2012 (US$ million)
- Fig.18: Nordion - Percentage of Revenue by Segment, 2012
- Nordion - Sales and Earning by Segment, 2010-2012 (US$ million)
- Medical Isotope Segment Results
- Nordion - Medical Isotope Sales by Product Line, 2010-2012 (US$ million)
- Fig.19: Nordion - Percentage of Medical Isotope Revenue by Product Line,
2012
- Latest Results and 2013 Outlook
NOVELOS THERAPEUTICS
- 124I-CLR1404 (LIGHT)
- CLR1502 (GLOW2)
NUVIEW LIFE SCIENCES
- Alliance with Thomas Jefferson University
- VPAC1 For Imaging Prostate Cancer
- NLS-VPAC For Imaging Breast Cancer
- NLS-VPAC1 Labelled with Ga-68
- NVLS/FXA-18 For Cardiovascular Disease
ONCOVISION
- Albira PET/SPECT/CT System
- Mammi Breast PET Imaging System
PERKINELMER
- Recent Key Events
- Fluorescence Molecular Tomography Imaging Systems
- Multispecies Imaging Module
- Imaging Agents
- Caliper Life Sciences' Pre-Clinical Imaging Systems
- IVIS Imaging Systems
- Quantum FX MicroCT System
- Living Image Multi Modality Software Module and the Mouse Imaging Shuttle
- Maestro MI Systems
- Current Alliances
- MosaMedix
- DuPont
- AntiCancer
- Merck
- Stanford University
- Massachusetts General Hospital
PHARMALUCENCE
PHILIPS HEALTHCARE
- Recent Key Events
- Nuclear Medicine Products
- Ingenuity TF PET/MR
- PET/CT
- SPECT/CT Systems
- BrightView SPECT
- Nuclear Gamma Cameras
- IntelliSpace Portal
- Extended Brilliance Workspace
- Pre-Clinical Imaging
- Research and Development
- High Tech Campus
- Molecular Imaging R&D Projects
- Research Alliances
- Distribution and Licensing Agreements
- ROSATOM
- Bioscan
- Sun MicroSystems
- Financial Performance
- Philips Healthcare: Operating Results, 2008-2012 (EUR million)
- Fig.20: Philips Healthcare - Revenue by Segment, 2012
- Fig.21: Philips Healthcare - Revenue by Region, 2012
PIRAMAL ENTERPRISES
- Research and Development
- Florbetaben PET Tracer
- Ga68-Bombesin for Prostate Cancer PET Imaging
- F-18-Labelled Bombesin Analogue for Imaging Prostate Cancer
- Al18F-1 for Prostate Cancer Imaging
- FSPG for Tumour Imaging
- L-5-F-18-ethoxy-Tryptophan for Tumour-Specific Imaging
- Current Alliances
POSITRON
- Recent Key Events
- Products and Services
- PET Products
- PosiRx Radiopharmaceutical System
- Tech-Assist
- Current Alliances and Contracts
- Jubilant DraxImage
- Institute of Nuclear Research, Troitsk, Russia
- Amerinet
- ARRONAX Cyclotron Facility, France
- Covidien
- Financial Performance
- Positron - Operating Results, 2007-2011 (US$ thousand)
- Latest Results
PROGENICS PHARMACEUTICALS
- Recent Key Events
- 99mTc-MIP-1404
PROPORTIONAL TECHNOLOGIES
- Cu-62 Micro-generator
- Products in Development
- PET Camera for Breast Imaging
- PET Camera for Small Animal Studies
SCINTOMICS
- Products
- Hotbox-III (HB-III)
- GallElut
- GRP Modules
- μ-ICR
- InViala
SEDECAL
- SuperArgus Pre-Clinical MI Products
SENO MEDICAL INSTRUMENTS
SHIMADZU
- MI Products
- PET Systems
- PET/CT Systems
- Clairvivo Pre-Clinical PET System
- Research Agreement with the National Cancer Center, Tokyo, Japan
SIEMENS HEALTHCARE
- Recent Key Events
- Molecular Imaging and PET Products
- Biograph mMR MRI-PET System
- PET/CT
- SPECT and SPECT/CT Systems
- MI Workstations and Software
- Pre-Clinical Imaging
- Biomarkers
- R&D Activities
- Siemens Molecular Imaging Biomarker Research
- Research Agreements
- Supply, Distribution and Licensing Agreements
- Avid Radiopharmaceuticals (Eli Lilly)
- Cleveland Clinic
- Financial Performance
- Fig.22: Siemens Healthcare: Sales by Location of Customer, 2012
- Latest Results
SOFIE BIOSCIENCES
- Genisys4
- 18F-FAC Probes
- ELIXYS
SPECTRUM DYNAMICS
- D-SPECT Cardiac Imaging System
TRIAD ISOTOPES
ULTRASPECT
UNITED PHARMACY PARTNERS
VISUALSONICS (FUJIFILM SONOSITE)
- Recent Key Events
- Products
- Vevo LAZR Photoacoustic Imaging System
- Vevo 2100
- Vevo 770
- MicroMarker Contrast Agent Kits
- Current Alliances
- Seno Medical Instruments
- Bracco
- University of Virginia
- WILEX
- Redectane
- Alliance with IBA Group
APPENDICES
- APPENDIX 1 - LIST OF ABBREVIATIONS
- APPENDIX 2 - REPORT METHODOLOGY
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
